Other molecules targeting specific clock components (He et al., 2016; Chen et al., 2018) need careful evaluation of their utility in the prevention or treatment of NAFLD, through clinical trials assessing the long-term safety and efficacy of these therapies. The gene discussed is CLOCK; the disease is metabolic dysfunction-associated steatotic liver disease.